Last €102.80 EUR
Change Today +1.35 / 1.33%
Volume 10.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:34 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Open
€101.17
Previous Close
€101.45
Day High
€102.80
Day Low
€101.06
52 Week High
09/25/14 - €109.15
52 Week Low
10/28/13 - €59.72
Market Cap
4.9B
Average Volume 10 Days
8.3
EPS TTM
--
Shares Outstanding
47.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTH)

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

706 Employees
Last Reported Date: 02/25/14
Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $992.7K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $808.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $543.8K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

united therapeutics corp (UTH) Key Developments

United Therapeutics Corporation Presents at Leerink Rare Disease Roundtable, Oct-01-2014 03:35 PM

United Therapeutics Corporation Presents at Leerink Rare Disease Roundtable, Oct-01-2014 03:35 PM. Venue: Le Parker Meridian Hotel, New York, New York, United States.

United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension

Pluristem Therapeutics Inc. announced that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem's PLacental eXpanded (PLX-PAD) cells in patients diagnosed with pulmonary arterial hypertension (PAH). PAH, with a global market estimated at approximately $3 billion, is characterized by abnormally high blood pressure in the arteries of the lungs; it can disrupt lung and heart function, to debilitating conditions such as heart failure. The Phase I study, being conducted in Australia, is an open-label, dose-escalation study designed to enroll 9 patients diagnosed with PAH. The first cohort of 3 patients has received 0.5 million PLX cells per kilogram body weight. An independent Data Safety Monitoring Board recommended advancement to the second cohort. The second cohort will receive 1 million cells per kilogram, while the third cohort is planned to be administered 2 million cells per kilogram. The primary endpoint of the study is the safety of PLX-PAD cells, which will be evaluated at 12 weeks and one year after dosing. Secondary efficacy endpoints are to be measured at six weeks post-treatment in order to assess changes in the ability to exercise, disease severity and cardio-respiratory function; measures include six-minute walk distance and cardio-pulmonary hemodynamic parameters evaluated via right heart catheterization and echocardiogram.

United Therapeutics Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014

United Therapeutics Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 . Venue: The Grand Hyatt Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €102.80 EUR +1.35

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.112.10 CHF -0.30
Alexion Pharmaceuticals Inc $190.29 USD +4.37
Celanese Corp $58.35 USD +0.50
Nippon Shinyaku Co Ltd ¥3,240 JPY +40.00
Vertex Pharmaceuticals Inc $109.91 USD +1.82
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 25.6x
Price/Sales 5.2x
Price/Book 5.3x
Price/Cash Flow 22.2x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.